This study combined pegylated IL-10 with FOLFOX in previously treated metastatic pancreatic cancer patients and, unfortunately, that did not result in improvement in survival outcomes, leading to further disappointment[61]. Here, IL10 is linked to familial pancreatic carcinoma.